Physician profile
Daniel B Johnson
NPI 1811448426
$2,064.17
in general payments reported to CMS, 2019-2025
27 companies · $907 in 2025
The $907 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $87.58 · 2022: $252 · 2023: $350 · 2024: $467 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $273.86 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $249.82 | 2023-2025 | |
| Novo Nordisk INC | $245.39 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $241.55 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $132.80 | 2022-2025 | Airsupra |
| Pfizer INC. | $114.03 | 2024-2025 | |
| Amgen INC. | $106.52 | 2021-2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $95.62 | 2021-2024 | |
| Exact Sciences Corporation | $88.95 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.37 | 2023-2025 | Xifaxan, Trulance |
| Corcept Therapeutics | $50.45 | 2025 | Korlym |
| Abbott Laboratories | $48.11 | 2022-2023 | Proclaim |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.27 | 2022 | |
| Tactile Systems Technology INC | $34.74 | 2023-2024 | Flexitouch Plus, Entre Plus |
| Vifor Pharma, INC. | $34.46 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $33.84 | 2023-2025 | Keveyis, Gvoke Hypopen |
| Verona Pharma, INC. | $23.70 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $22.54 | 2024 | Inspire |
| Alexion Pharmaceuticals, INC. | $20.77 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.03 | 2024 | Nuzyra |
| Sonex Health, INC. | $17.79 | 2025 | Sx-One Microknife |
| Fresenius USA Marketing, INC. | $16.38 | 2021 | |
| Phathom Pharmaceuticals, INC. | $16.23 | 2025 | Voquezna |
| Aurinia Pharma U.S., INC. | $15.28 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.14 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $13.82 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $13.71 | 2023 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.